Literature DB >> 21339063

Risk for second primary non-breast cancer in pre- and postmenopausal women with breast cancer not treated with chemotherapy, radiotherapy or endocrine therapy.

Rikke Langballe1, Jørgen H Olsen, Michael Andersson, Lene Mellemkjær.   

Abstract

INTRODUCTION: We investigated the risk for a second primary cancer in pre- and postmenopausal women with breast cancer treated by surgery alone, to assess the importance of non-treatment factors and menopausal status. PATIENTS AND METHODS: The cohort comprised 14,151 women with breast cancer diagnosed during 1977-2006, who did not receive radiotherapy or systemic adjuvant therapy. They were identified in the nationwide clinical database of the Danish Breast Cancer Cooperative Group. The women were followed for a second primary cancer other than breast cancer in the Danish Cancer Registry, and risk was quantified as standardised incidence ratios (SIRs).
RESULTS: Women with breast cancer diagnosed before menopause had an 18% greater overall risk for a second primary non-breast cancer than the general female population (95% confidence interval [CI], 1.06-1.32). The excess was confined to cancers of the endometrium (1.5; 95% CI, 1.0-2.0) and ovaries (1.8; 95% CI, 1.2-2.4). Rare histological subtypes of breast cancer were associated with these two cancer sites. Women with breast cancer after menopause had no overall excess risk for a second cancer (SIR, 0.98; 95% CI, 0.92-1.04).
CONCLUSION: An excess risk for second non-breast cancers related to non-treatment factors is seen primarily in breast cancer patients who were premenopausal at diagnosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21339063     DOI: 10.1016/j.ejca.2011.01.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Carcinoma showing thymus-like elements of the thyroid gland: report of three cases including one case with breast cancer history.

Authors:  Guanjun Zhang; Xi Liu; Wei Huang; Xiaofeng Li; Marianne Johnstone; Yuan Deng; Yongqiang Ke; Quentin M Nunes; Hongyan Wang; Yili Wang; Xuebin Zhang
Journal:  Pathol Oncol Res       Date:  2014-11-29       Impact factor: 3.201

2.  Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma.

Authors:  Qijun Li; Yong Dong; Yubin Pan; Honglin Tang; Da Li
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

3.  Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.

Authors:  Raffaella Marcheselli; Luigi Marcheselli; Laura Cortesi; Alessia Bari; Claudia Cirilli; Samantha Pozzi; Paola Ferri; Martina Napolitano; Massimo Federico; Stefano Sacchi
Journal:  J Breast Cancer       Date:  2015-12-23       Impact factor: 3.588

4.  Use of microwave ablation in the treatment of patients with multiple primary malignant tumors.

Authors:  Yue Han; Na Shao; Xiaoming Xi; Xuezhi Hao
Journal:  Thorac Cancer       Date:  2017-05-31       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.